By Drug Class / Mechanism

Biologics & Monoclonal Antibodies Market Analysis

Cross-industry research covering Biologics & Monoclonal Antibodies across 1 market reportspanning Pharmaceuticals.

1 Reports
1 Industries

Reports Covering Biologics & Monoclonal Antibodies

Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR

Pharmaceuticals·Market: USD 25.3 Billion (2025)·CAGR: 6.4%

Bezlotoxumab (Zinplava) for C. difficile recurrence prevention anchors this segment alongside investigational anti-biofilm monoclonals. BLA pathway complexity and REMS considerations limit near-term entrant volume, but the fast-track and breakthrough therapy designation pipeline for novel anti-infective biologics is the strongest it has been in a decade.

8%

Market Share

8.4%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments